IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML). Imatinib directly inhibits the constitutive tyrosine kinase activity. Imatinib binds to BCR-ABL kin...

Full description

Saved in:

Bibliographic Details
Main Author:	Tomasz Sacha
Format:	Article
Language:	English
Published:	PAGEPress Publications 2013-12-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Chronic myeloid leukemia, Imatinib
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/1357
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Massimo Breccia, et al.
Published: (2011-05-01)

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development
by: Irina Badralexi, et al.
Published: (2024-12-01)

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
by: Hongpeng Duan, et al.
Published: (2024-12-01)

THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)

Targeting the insulin-like growth factor-1 receptor to overcome imatinib resistance in chronic myeloid leukemia
by: Seiichi Okabe, et al.
Published: (2024-12-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY
by: Jyotsna Kapoor, et al.
Published: (2015-02-01)

Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with cronic myeloid leukemia treated with imatinib
by: Bojan Labachevski, et al.
Published: (2024-12-01)

OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY
by: Mohamed Amine BEKADJA
Published: (2017-10-01)

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
by: Meng-Tung Hsu, et al.
Published: (2025-01-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: Kotlyarchuk K., et al.
Published: (2015-09-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Chronic myeloid leukemia following nasopharyngeal carcinoma
by: olfa kassar
Published: (2014-08-01)

Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
by: Aytan Shirinova
Published: (2024-03-01)

Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review
by: Domenico Santorsola, et al.
Published: (2015-02-01)

TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
by: Michele Baccarani, et al.
Published: (2014-01-01)

Unraveling the unexpected: A rare case of filariasis in chronic myeloid leukemia with a review of the literature
by: Nikhil Kumar
Published: (2024-09-01)

Delayed manifestation of proliferative retinopathy associated with chronic myeloid leukemia
by: Alan Chew Bonilla, et al.
Published: (2024-12-01)

Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2
by: Junyi Wei, et al.
Published: (2024-11-01)

Impact of Hemoglobin, Leucocyte and Thrombocyte Levels at Diagnosis on the Survival Outcomes of Chronic Myeloid Leukemia Patients
by: Taha Ulutan Kars, et al.
Published: (2024-02-01)

Role of MicroRNAs in Chronic Myeloid Leukemia (CML) Treatment, Biomarkers, and Resistance to Tyrosine Kinase Inhibitor: A Bioinformatics-Based Analysis
by: Syarifah Faezah binti Syed Mohamad, et al.
Published: (2024-11-01)

Anuric Acute Kidney Injury in Chronic Myeloid Leukemia: A Rare Complication Case
by: Angela Kimberly Tjahjadi, et al.
Published: (2024-10-01)

Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the <i>BCR-ABL</i> Gene: An Hierarchical Biochemoinformatics Analysis
by: Vitor H. da S. Sanches, et al.
Published: (2024-11-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA
by: Naveen Gupta, et al.
Published: (2021-01-01)

IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
by: Federica Sorà, et al.
Published: (2021-10-01)

THE PROGNOSTIC SIGNIFICANCE OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM IN EGYPTIAN CHRONIC MYELOID LEUKEMIA
by: Enas A Dammag, et al.
Published: (2020-01-01)

Data and implication based comparison of two chronic myeloid leukemia models
by: R. A. Everett, et al.
Published: (2013-07-01)

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
by: Judit Demeter, et al.
Published: (2021-02-01)

Coexistence of P190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report
by: najmaldin saki, et al.
Published: (2016-01-01)

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
by: Ivan Tonev, et al.
Published: (2025-01-01)

http://www.aulamedica.es/fh/pdf/10518.pdf
by: Marta García-Queiruga, et al.
Published: (2016-05-01)

Novel targeted therapies in chronic myeloid leukemia
by: Muhammad Sameer Ashaq, et al.
Published: (2024-12-01)

Prognostic criteria of chronic myeloid leukemia by changes platelets sizes
by: Shorop Y.V., et al.
Published: (2016-03-01)

Prognostic criteria of chronic myeloid leukemia by changes platelets sizes.
by: Y. V. Shorop, et al.
Published: (2016-03-01)

Interaction of xanthoxyletin with protein, molecular docking and antitumor activity in human chronic myeloid leukemia K562 cells
by: Chen Wang, et al.
Published: (2024-12-01)